TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03197285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EYE-CERVICAL RE-EDUCATION PROGRAM
Description: Subjects received a total of ten sessions on alternate days.~This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area with the following phases:~1. To stimulate ocular mobility without including the cervical movement. The patient was placed in the supine position and the physiotherapist seated, at the height of the head.~2. To exercise cervical mobility with restricted eye movement. The patient is placed on a rotating stool. The ocular mobility is excluded with opaque glasses that allowed exclusively the foveal vision~3. Finally we stimulate eye and neck movement coordination. The patient continued to sit on the stool, this time without the glasses.
Study: NCT01119339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004
Description: LAS 41004 dosage 2, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004
Description: LAS 41004 dosage 3, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004
Description: LAS 41004 dosage 4, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004
Description: LAS 41004 , dosage 5, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004 dosage 6
Description: LAS 41004, dosage 6, once daily
Study: NCT00342355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Didanosine
Description: \<60 kg/125 mg twice daily or \>60kg/200 mg twice daily
Study: NCT01119339

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Reference, once daily
Study: NCT03428815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthesis suspension liner
Description: Liners out of phase change material will be fitted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis suspension liner
Description: Liners out of phase change material will be fitted
Study: NCT04499417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyostimulation Whole-Body-Workout
Description: Electromyostimulation - intensity 5 (muscle stimulation)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electromyostimulation Sham Whole-Body-Workout
Description: Electromyostimulation - intensity 0 (no muscle stimulation)
Study: NCT04223037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis Vaccine produced by IMBCAMS
Description: Dosage form: 0.5mL/vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis Vaccine produced by IMBCAMS
Description: Dosage form: 0.5mL/vial
Study: NCT03219463

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginger
Description: 3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
Study: NCT04223037

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis Vaccine produced by Liaoning Chenda
Description: Dosage form: 0.5mL/vial
Study: NCT02393755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study: NCT00342355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 300 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 300 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: r/LPV 400mg/100mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: r/LPV 400mg/100mg twice daily
Study: NCT02071238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pamphlet
Description: Written pamphlet outlining the risks of surgery as discussed in consultation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Consultation
Description: Informed consent discussion in group-format
Study: NCT03392766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single lumen tube and bronchial blocker
Description: neck collar apply. fibreoptic intubation with single lumen tube and bronchial blocker.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double lumen tube
Description: neck collar apply. fibreoptic intubation with double lumen tube.
Study: NCT01832961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flutter valve exercises
Description: 30 minutes of flutter exercises

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Flutter Sham exercises
Description: 30 minutes of flutter-sham exercises

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flutter and bronchodilator exercises
Description: Flutter + bronchodilator exercises with an interval of 3 to 5 days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Flutter and bronchodilator exercises
Description: Flutter + bronchodilator exercises with an interval of 3 to 5 days
Study: NCT01058603

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: - Conventional culture medium for IVF
Description: Embryos are cultured on conventional medium and transferred at Day 3. Supernumerary good quality embryos are frozen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: - Endocell®
Description: Embryos are cultured on ENDOCELL® from Day 2 to Day 5 (Blastocyst stage) One embryo is transferred at Day 5. Supernumerary good quality embryos are frozen.
Study: NCT02300649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, Transesophageal echocardiography(TEE)
Description: Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.
Study: NCT00124306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Amitriptyline will be titrated over a 6-week period as tolerated, to a maximum dose of 75mg. During the 6-week titration period, the patient who cannot tolerate a scheduled increased dose may adjust the medication dose for tolerance by tapering down one 25mg tablet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be dosed exactly as active arm.
Study: NCT01530139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 1
Description: Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
Study: NCT02393755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03757923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB METFORMIN
Description: INSULIN SENSITIZING AGENTS
Study: NCT01530139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 2
Description: Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 3
Description: Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Level 0
Description: Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
Study: NCT03906682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAP Club
Description: RAP Club was adapted from a trauma treatment program called Structured Psychotherapy for Adolescents Responding to Chronic Stress (SPARCS). Core program components include psychoeducation, mindfulness, and cognitive-behavioral strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Topics
Description: Co-investigator Dr. Sibinga developed the Healthy Topics curriculum to function as an active control condition for randomized controlled trials in both clinic-based and school-based studies of mindfulness instruction for urban youth. Adapted from the Glencoe Health Curriculum (McGraw Hill), it was designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
Study: NCT03757923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB PIOGLITAZONE
Description: INSULIN SENSITIZING AGENT
Study: NCT03296683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRA device imaging
Description: MIRA Device imaging for adjunctive detection of breast cancer
Study: NCT04108390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: For this intervention, the physiotherapist will be placed a needle in the gluteus medius trigger point from 8 to 15 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: For this intervention, the physiotherapist will be placed a needle in the gluteus medius trigger point from 8 to 15 times.
Study: NCT02322996

Intervention type: OTHER
Intervention: questionnaires
Description: The deep phenotyping of acute pain will be conducted using the oral surgery model. Before surgery, subjects will undergo QST and answer short-form questionnaires related to pain and activities of daily living.
Study: NCT04597450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 - 30 mg/day, capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
Study: NCT03094728

Intervention type: DIAGNOSTIC_TEST
Intervention: HLA cross matching
Description: HLA Typing and Mismatch~Cross matching (total and autocross):~Cross match involves placing recipient serum onto donor lymphocytes and a cytotoxic reaction (deemed 'positive') suggests the presence of preformed donor specific antibodies (DSAs),Second, the original crossmatch should be repeated with the addition of the agent Dithiothreitol (DTT). DTT reduces the disulfide bonds in IgM thereby preventing IgM antibodies from generating a positive result.
Study: NCT03219463

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: 3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
Study: NCT04597060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermomechanical system with corticosteroids
Description: The device in this study using Novoxel - Tixel®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corticosteroid injection
Description: corticosteroid injection using TA 10mg/ml
Study: NCT01167985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IABN
Description: Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IABN
Description: patients with molar teeth diagnosed with healthy pulp or irreversible pulpitis, and need root canal treatment, will be asked to participate in the study. After cleaning the teeth following a standard protocol, a sterile cotton wool will be placed in the pulp chamber. provisional restoration with and without nanoparticles will seal the teeth between apointments. After a month the cotton wool will be taken out and tansferred to the laboratory. The root canal treatment will continue following the standard protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IABN
Description: Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
Study: NCT03403387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GlutenShield
Description: combination probiotic, prebiotic, and enzyme supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Avicel (cellulose) and bentonite powder
Study: NCT00174772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy
Description: docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin
Description: docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
Study: NCT01230203

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed tomography scan versus color duplex ultrasound
Description: Computed tomography scan versus color duplex ultrasound
Study: NCT02700087

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ranitidine or famotidine
Description: Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranitidine or famotidine
Description: Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
Study: NCT05519332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous vertebral-disc plasty
Description: percutaneous vertebroplasty combined percutaneous cement discoplasty
Study: NCT01513200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Description: UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unfractionated heparin (UFH)
Description: UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia
Description: Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0.9%, sterile, for infusion)
Description: Saline (placebo) Constant IV infusion for 4 hours
Study: NCT02069340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02677311

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pelvic Ultrasound
Description: Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pelvic Ultrasound
Description: Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
Study: NCT00156156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: Asoprisnil 10 mg Tablet, oral Daily for up to 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: Asoprisnil 25 mg Tablet, oral Daily for up to 2 years
Study: NCT03907839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical trials
Description: examined two type of training on cognitive parameters for COPD patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical trials
Description: examined two type of training on cognitive parameters for COPD patients
Study: NCT00527488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose of 32 mg administered as a single administration will be evaluated for 42 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose of 64 mg administered as a single administration will be evaluated for 42 days.
Study: NCT01958827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection.
Study: NCT03343418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: Desmopressin is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given desmopressin 0,3 microgram.kg-1. After desmopressin infusion, bleeding treatment will follow the predefined standardized treatment regimen.
Study: NCT00670696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapydan
Description: Topical anaesthetic plaster

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracaine gel
Description: Topical tetracaine gel
Study: NCT01013974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 250 μg
Description: Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 500 μg
Description: Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 1000 μg
Description: Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719 matching Placebo
Description: Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
Study: NCT00648401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride Extended-Release Capsules, 300 mg
Description: 300mg, single dose fed
Study: NCT02603133

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Awe
Description: This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Awe
Description: This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.
Study: NCT00648401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verelan® PM Extended-Release Capsules, 300 mg
Description: 300mg, single dose fed